Cargando…

Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a reduced number of circulating platelets due to immune-mediated destruction and decreased platelet production in the bone marrow. Thrombopoietin receptor agonists (TPO-RAs) are highly effective and widely used in the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsykunova, Galina, Ghanima, Waleed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977771/ https://www.ncbi.nlm.nih.gov/pubmed/35386180 http://dx.doi.org/10.2147/TCRM.S251672

Ejemplares similares

PB2608: THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA (ITP) IN NORWAY IN THE REAL LIFE – ANALYSIS OF THE NOR-ITP REGISTRY
por: Ilicheva, Ekaterina, et al.
Publicado: (2023)

Immune Thrombocytopenia (ITP): Current Limitations in Patient Management
por: Terrell, Deirdra R., et al.
Publicado: (2020)

Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease
por: Cheloff, Abraham Z, et al.
Publicado: (2019)

How do patients and physicians perceive immune thrombocytopenia (ITP) as a disease? Results from Indian analysis of ITP World Impact Survey (I-WISh)
por: Chakrabarti, Prantar, et al.
Publicado: (2022)

Thrombotic Complications in Immune Thrombocytopenia Patients Treated with Avatrombopag
por: Abdelsamia, Mahmoud, et al.
Publicado: (2023)

Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life
por: Cooper, Nichola, et al.
Publicado: (2020)

Avatrombopag: A Review in Thrombocytopenia
por: Markham, Anthony
Publicado: (2021)

Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia
por: Viana, Ricardo, et al.
Publicado: (2021)

PB2623: AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA
por: An, Qi, et al.
Publicado: (2023)

PB2637: OUR EXPERIENCE WITH AVATROMBOPAG TREATMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Cervinek, Libor
Publicado: (2023)

Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
por: Mladsi, Deirdre, et al.
Publicado: (2020)

Correction to: Avatrombopag: A Review in Thrombocytopenia
por: Markham, Anthony
Publicado: (2021)

Complete Guide to the CITP Body of Knowledge
por: Singleton, Tommie
Publicado: (2017)

P1589: PATIENT (PT) AND PHYSICIAN (MD) PERCEPTIONS OF THE BURDEN OF IMMUNE THROMBOCYTOPENIA (ITP) AND ITS MANAGEMENT: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) 2.0
por: Cooper, Nichola, et al.
Publicado: (2023)

PB2308: QUALITY OF LIFE AND CLINICAL OUTCOMES IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) DURING TREATMENT WITH ROMIPLOSTIM IN A REAL-WORLD SETTING
por: Ionova, T., et al.
Publicado: (2022)

Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag
por: Abdela, Jemal
Publicado: (2019)

Acute Immune Thrombocytopenia (ITP) Following COVID-19 Vaccination in a Patient With Previously Stable ITP
por: Jawed, Muzamil, et al.
Publicado: (2021)

Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives
por: Zitek, Tony, et al.
Publicado: (2022)

Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study
por: Oladapo, Abiola, et al.
Publicado: (2023)

PB2622: A PROSPECTIVE, OPEN-LABEL ONGOING STUDY OF SAFETY AND TREATMENT SATISFACTION IN ADULT IMMUNE THROMBOCYTOPENIA (ITP) SUBJECTS AFTER SWITCHING TO AVATROMBOPAG FROM ELTROMBOPAG OR ROMIPLOSTIM
por: Kolodny, Scott, et al.
Publicado: (2023)

Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
por: Zufferey, Anne, et al.
Publicado: (2017)

Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment
por: Cooper, Nichola, et al.
Publicado: (2020)

Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis
por: Wojciechowski, Piotr, et al.
Publicado: (2021)

Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments
por: Aiello, Andrea, et al.
Publicado: (2023)

Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China
por: Mei, Heng, et al.
Publicado: (2023)

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives
por: Vianelli, Nicola, et al.
Publicado: (2022)

Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure
por: Satapathy, Sanjaya K., et al.
Publicado: (2023)

Response to rituximab in children and adults with immune thrombocytopenia (ITP)
por: Harris, Emily M., et al.
Publicado: (2021)

Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation
por: Zhou, Meng, et al.
Publicado: (2022)

Immune Thrombocytopenia (ITP) Secondary to Subclinical Hashimoto’s Thyroiditis: Role of Levothyroxine in Improving the Clinical Outcome of ITP
por: Tahir, Hassan, et al.
Publicado: (2016)

Avatrombopag ethnic sensitivity analysis in chronic liver disease and thrombocytopenia patients: individual-level pooled analysis
por: Lu, Jun, et al.
Publicado: (2022)

Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group
por: Mingot-Castellano, M. Eva, et al.
Publicado: (2019)

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
por: Jurczak, Wojciech, et al.
Publicado: (2018)

Secondary immune thrombocytopenia (ITP) as an initial presentation of Whipple’s disease
por: Priest, David H., et al.
Publicado: (2017)

Proposal for a New Protocol for the Management of Immune Thrombocytopenia (ITP)
por: González-López, Tomás José, et al.
Publicado: (2022)

PB2636: VAYHIT1: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VERSUS PLACEBO IN ADDITION TO FIRST-LINE CORTICOSTEROIDS IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
por: Cooper, Nichola, et al.
Publicado: (2023)

Overuse of corticosteroids in patients with immune thrombocytopenia (ITP) between 2011 and 2017 in the United States
por: Cuker, Adam, et al.
Publicado: (2023)

The 4 T's of ITP: Tailoring Therapies to Treat Thrombocytopenia
por: Hughes, David
Publicado: (2022)

The Role of Leptin in Childhood Immune Thrombocytopenia (ITP): An Anti-Inflammatory Agent?
por: Thomas, Iason, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dvps99bgudko6kkfdtf794d446